Table 1.
Demographics of enrolled volunteers.
| Vaccination Phase - Safety Population |
Challenge Phase - ITT Population |
||||||
|---|---|---|---|---|---|---|---|
| Flexyn2a N = 34 |
Placebo N = 33 |
Total N = 67 |
Flexyn2a N = 30 |
Placebo N = 29 |
Total N = 59 |
||
| Gender - N (%) | Female | 10 (29.4) | 11 (33.3) | 21 (31.3) | 9 (30.0) | 8 (27.6) | 17 (28.8) |
| Male | 24 (70.6) | 22 (66.7) | 46 (68.7) | 21 (70.0) | 21 (72.4) | 42 (71.2) | |
| Age (yrs) | Mean | 36.6 | 34.4 | 35.5 | 36.5 | 34.3 | 35.4 |
| Median | 35.1 | 34.5 | 34.8 | 35.1 | 34.5 | 34.8 | |
| Range | 23.5–49.8 | 22.3–50.3 | 22.3–50.3 | 23.5–49.8 | 22.3–50.3 | 22.3–50.3 | |
| Race - N (%) | American Indian/Alaskan Native, Black or African American* |
3 (8.8) | 1 (3.0) | 4 (6.0) | 3 (10.0) | 0 (0.0) | 3 (5.1) |
| Asian | 0 (0.0) | 1 (3.0) | 1 (1.5) | 0 (0.0) | 1 (3.4) | 1 (1.7) | |
| Black or African American | 26 (76.5) | 28 (84.8) | 54 (80.6) | 22 (73.3) | 25 (86.2) | 47 (79.7) | |
| Hispanic | 1 (2.9) | 0 (0.0) | 1 (1.5) | 1 (3.3) | 0 (0.0) | 1 (1.7) | |
| White | 4 (11.8) | 3 (9.1) | 7 (10.4) | 4 (13.3) | 3 (10.3) | 7 (11.9) | |
N= number;%= percent; ITT= intention to treat; yrs.= years.
*These subjects reported mixed race.